Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

5(100.0%)

5Total

Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00362414Phase 2Completed

Beta-hCG + Erythropoietin in Acute Stroke

Role: collaborator

NCT00938314Phase 2Terminated

Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Role: lead

NCT00715364Phase 2Withdrawn

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Role: lead

NCT01239706Phase 2Unknown

Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1

Role: collaborator

NCT00663416Phase 2Terminated

REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Role: lead

All 5 trials loaded